Feb 19 (Reuters) - Harmony Biosciences Holdings Inc HRMY.O:
HARMONY BIOSCIENCES PROVIDES UPDATE ON THE STATUS OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR PITOLISANT IN IDIOPATHIC HYPERSOMNIA
HARMONY BIOSCIENCES HOLDINGS INC - 2025 NET REVENUE GUIDANCE REMAINS UNCHANGED AT $820-$860 MILLION
HARMONY BIOSCIENCES HOLDINGS INC - TO INITIATE PHASE 3 TRIAL OF PITOLISANT HD IN Q4 2025
HARMONY BIOSCIENCES HOLDINGS INC - RECEIVES FDA REFUSAL TO FILE LETTER FOR PITOLISANT
HARMONY BIOSCIENCES -ON TRACK TO INITIATE A PHASE 3 REGISTRATIONAL TRIAL OF PITOLISANT HD IN IH IN Q4 2025, WITH A TARGET PDUFA DATE IN 2028
Source text: ID:nBw4VR77Na
Further company coverage: HRMY.O